Biotech stocks took a tumble on Monday with the XBI S&P biotech ETF and IBB Nasdaq biotech ETF each falling by more than 1 percent.
"If you're playing biotech, you're counting on little companies doing something amazing and hopefully getting bought by a big company," Nadig said on CNBC's"ETF Edge" on Monday."We saw that in the last couple of weeks when Spark Therapeutics got bought by Roche, that was a significant position in XBI. It's barely in IBB."
To Ben Johnson, director of global ETF research at Morningstar, the equal-weighted XBI ETF offers big returns, but volatility in the biotech segment means investors need to have a strong stomach.
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Watch now: ETF Edge on the market sell-off, and the Tesla-heavy ETF that's beating the S&P this year
Прочитайте больше »
Biotech stocks are going wild, and these two could be your best bet for a bigger breakoutBiotech is blazing higher. One technician says it should continue to be a healthy trade.
Прочитайте больше »